Citius Pharmaceuticals Inc CTXR 深 滬
等待開盤 03-26 09:30:00 美东时间
0.72
+0.010
+1.41%
華盛通- 最 高0.7498
- 今 開0.7226
- 成交量 42.68万股
- 最 低 0.7193
- 昨 收 0.71
- 總市值 1611.10万
- 52周最高 2.48
- 市盈率 靜 --
- 換手率 1.91%
- 52周最低 0.63
- 委 比 96.17%
- 總股本 2237.64万
- 歷史最高 137.25
- 量 比 0.91
- 振 幅 4.30%
- 歷史最低 0.63
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Oncology Announces Topline Results From Investigator‑Initiated Phase 1 Trial Of LYMPHIR Administered Prior To Commercial CD19‑Directed CAR‑T Therapy In High‑Risk DLBCL; Co Says LYMPHIR Was Well-Tolerated With No Dose-Limiting Toxicities Observed
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was
03-04 22:18
Citius Pharmaceuticals Inc. Announces Annual Stockholders Meeting
Citius Pharmaceuticals Inc. Announces Annual Stockholders Meeting Citius Pharmaceuticals Inc. will hold its annual meeting of stockholders on April 6, 2026, at the company’s headquarters in Cranford, New Jersey. At the meeting, shareholders will vote on the election of seven directors to serve until
02-24 21:01
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Non-dilutive capital supports continued execution and value creation CRANFORD, N.J., Feb. 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CT...
02-24 21:00
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know
Citius Pharmaceuticals (NASDAQ:CTXR) reported its Q1 earnings results on Friday...
02-13 22:14
Citius Pharma Q1 EPS $(0.38) Misses $(0.30) Estimate, Sales $3.944M Beat $3.455M Estimate
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.30) by 26.67 percent. This is a 70.77 percent increase over losses of $(1.30) per share from
02-13 22:13
Citius Pharmaceuticals reports first revenue of $3.9 mln
Citius Pharmaceuticals reports first revenue of $3.9 mln Overview Biopharmaceutical firm reported first revenue of $3.9 mln from LYMPHIR launch in Q1 2026 Net loss for Q1 2026 was $8.2 mln, with basic EPS of -$0.38 Citius Oncology launched LYMPHIR for cutaneous T-cell lymphoma in December 2025 Outlo
02-13 21:08
Citius Pharma Q1 stock-based compensation expense rises to USD 3.56 million, up 97%
Citius Pharma Q1 stock-based compensation expense rises to USD 3.56 million, up 97% Citius Pharmaceuticals Inc. reported its earnings for the three months ended December 31, 2025. The company posted interest income of USD 0.05 million for the quarter. Interest expense totaled USD 0.16 million for th
02-13 21:01
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- C...
02-13 21:00
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why
Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.
2025-12-24 14:56
Citius Pharma Q4 EPS $(0.11) Beats $(0.43) Estimate
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.43) by 74.42 percent. This is a 93.6 percent increase over losses of $(1.72) per share from the
2025-12-24 05:36
